Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01140685
First received: February 17, 2010
Last updated: June 8, 2010
Last verified: March 2010
  Purpose

This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).


Condition Phase
Lung Diseases
Phase 2

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • exhaled CO levels [ Time Frame: 2010-2011 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

induced sputum, exhaled CO levels


Enrollment: 70
Study Start Date: December 2009
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled

Criteria

Inclusion Criteria:

  • Male and female
  • Ages >/= 18 years
  • Diagnosed with one or more lung diseases
  • Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01140685

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Elizabeth Fierman, PHD Tel Aviv Sorasky Medical Center
  More Information

No publications provided

Responsible Party: ELIZABETH FIERMAN, PHD, Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT01140685     History of Changes
Other Study ID Numbers: TASMC-10-LF-669-CTIL
Study First Received: February 17, 2010
Last Updated: June 8, 2010
Health Authority: Israel: Ethics Commission

Keywords provided by Tel-Aviv Sourasky Medical Center:
mucus-stimulated (induced sputum)
lung disease (asthma, COPD, ILD and OLD)
HO-1 (heme oxigenase-1)
oxidative stress
CO (carbon monoxide)
The oxidative stress in lung diseases

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Carbon Monoxide
Antimetabolites
Gasotransmitters
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 27, 2014